GCG and Parkinson disease: Other randomized, double-blind, and placebo-controlled trials of GLP-1 RAs in PD patients are currently underway,1 testing the agents semaglutide (NCT03659682), liraglutide (NCT02953665), lixisenatide (NCT03439943), NLY01 (NCT04154072), or PT320 (NCT04269642) in PD patients, with additional phase 2 (NCT04305002) and phase 3 (NCT04232969) trial testing exenatide in PD patients in recruiting, highlighting the growing demand for discovery and development of GLP-1 RAs.